For instance, YBX1 inhibition can reduce PD-L1 expression, remodel the immunosuppressive tumor microenvironment, and enhance the efficacy of immune checkpoint inhibitors (ICIs), while also reversing chemoresistance and increasing tumor sensitivity to anticancer drugs (18). This evidence concerns the gene CD274 and neoplasm.